Media Advisory: Dr. Heinrich Roder, Biodesix CTO, To Speak At Precision Medicine World Conference
Media Advisory: Dr. Heinrich Roder, Biodesix CTO, to speak at precision medicine world conference
254 Results
Media Advisory: Dr. Heinrich Roder, Biodesix CTO, to speak at precision medicine world conference
Innovatus Capital partners joins as a new investor; Scott Hutton joins as COO
Biodesix and Professor Fred R. Hirsch announced a collaboration on a PD-L1 study
A new study published in the Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell lung cancer
Biodesix announced that it has acquired Integrated Diagnostics, Inc.
The Society for Advanced Bronchoscopy (SAB) will hold its second meeting: Hot Topics in Advanced Bronchoscopy.
Findings in the AACR Journal on melanoma patient outcomes after anti PD1 therapy; a serum protein signature predicted survival.
Bronchoscopy professionals in the United States need greater educational and practice-building support to ensure continued delivery of high-quality care for Americans
New data demonstrate that a blood-based proteomic test reliably assesses individual patient prognosis to inform treatment decisions.
Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex